How should I treat the anemia (Hb ~8 g/dL) in a 57‑year‑old man with end‑stage renal disease on thrice‑weekly hemodialysis, stage IV rectal adenocarcinoma, chronic right empyema, functional iron deficiency, currently on epoetin alfa 4000 U post‑dialysis and oral phosphate binders?

Management of Anemia in a 57-Year-Old Man on Hemodialysis with Stage IV Colon Cancer

Immediate Priority: Intravenous Iron Supplementation

Your patient has functional iron deficiency (TSAT 17%, ferritin 6.14 ng/mL) that is severely limiting his response to epoetin alfa; you must immediately initiate intravenous iron supplementation before considering any ESA dose escalation. 1

Why IV Iron is Essential Now

• Absolute iron deficiency is present: With ferritin 6.14 ng/mL (far below the target ≥100 ng/mL) and TSAT 17% (below the target ≥20%), this patient has both depleted iron stores and insufficient iron available for erythropoiesis. 2, 1

• Oral iron is ineffective in hemodialysis: Hemodialysis patients lose approximately 400–500 mg of iron every 3 months through dialyzer blood losses and phlebotomy, and hepcidin-mediated absorption blockade prevents adequate oral iron uptake. 1 More than 50% of ESRD patients on ESAs remain iron-deficient despite oral supplementation. 1

• Functional iron deficiency explains ESA hyporesponsiveness: The patient receives 4000 U epoetin alfa three times weekly (12,000 U/week total, approximately 150 U/kg/week for a 80 kg man), which is a reasonable maintenance dose, yet his hemoglobin is critically low at 7.9 g/dL. The most frequent cause of ESA hyporesponsiveness is iron deficiency. 1, 3

IV Iron Dosing Protocol

Administer iron sucrose 100 mg IV with each hemodialysis session (three times weekly) until iron stores are repleted, then transition to maintenance dosing of 25–125 mg weekly. 1

• Loading phase: Give 100 mg iron sucrose IV three times weekly for 8–10 doses (total 800–1000 mg over approximately 3 weeks) to rapidly correct the severe iron deficit. 2

• Maintenance phase: After repletion, continue 25–125 mg iron sucrose weekly to replace ongoing dialysis-related losses of approximately 400–500 mg every 3 months. 1

• Monitoring targets: Recheck TSAT and ferritin in 4 weeks; aim for TSAT ≥20% and ferritin ≥100 ng/mL (optimally ≥200 ng/mL for hemodialysis patients). 1, 3

• Safety ceiling: Withhold IV iron if ferritin exceeds 800 ng/mL or TSAT exceeds 50%, as further supplementation offers no benefit and may increase infection risk. 1

Critical Contraindication

Do not administer IV iron during active infection. 1 This patient has chronic right empyema thoracis; confirm that the empyema is stable and not acutely infected before initiating IV iron. If there is any clinical suspicion of active infection (fever, elevated WBC with left shift, worsening chest imaging), defer iron therapy until the infection resolves.

---

ESA Management: Continue Current Dose During Iron Repletion

Do not increase the epoetin alfa dose yet; maintain the current regimen of 4000 U subcutaneously post-dialysis three times weekly while you correct the iron deficiency. 1, 3

Rationale for Holding ESA Escalation

• Iron deficiency must be corrected first: Escalating ESA doses in the setting of iron deficiency is ineffective and wastes medication. The expected hemoglobin response to iron repletion alone is 1–2 g/dL within 4–8 weeks. 3

• Current dose is appropriate: At approximately 150 U/kg/week, the patient is receiving a standard maintenance dose. 2 ESA resistance is defined as failure to achieve hemoglobin ≥11 g/dL despite epoetin alfa doses >300 U/kg/week; this patient is well below that threshold. 1

When to Consider ESA Dose Adjustment

After 4 weeks of adequate IV iron supplementation (TSAT ≥20%, ferritin ≥100 ng/mL), if hemoglobin has not increased by ≥1 g/dL, increase the epoetin alfa dose by 25%. 1, 3

• Dose escalation: Increase from 4000 U to 5000 U post-dialysis three times weekly (total weekly dose from 12,000 U to 15,000 U). 1

• Reassess at 8 weeks total: If there is still no response despite confirmed adequate iron stores, consider ESA hyporesponsiveness from other causes (chronic inflammation from empyema, malignancy-related anemia, occult blood loss from colon cancer). 1, 3

---

Hemoglobin Target and Monitoring

Target hemoglobin 11–12 g/dL; do not exceed 12 g/dL, as higher targets increase mortality, cardiovascular events, and stroke risk. 1, 4

Evidence for Conservative Targets

• Mortality risk with higher targets: The Normal Hematocrit Study (NHS) demonstrated 27% higher all-cause mortality (HR 1.27,95% CI 1.04–1.54) when targeting hemoglobin 14 g/dL versus 10 g/dL in dialysis patients with cardiac disease. 4

• Cardiovascular events: The CHOIR trial showed a 34% increase in composite cardiovascular events (death, MI, stroke, CHF hospitalization; HR 1.34,95% CI 1.03–1.74) when targeting hemoglobin 13.5 g/dL versus 11.3 g/dL in CKD patients. 4

• Stroke risk: The TREAT trial demonstrated a 92% increase in stroke risk (HR 1.92,95% CI 1.38–2.68) with higher hemoglobin targets in diabetic CKD patients. 4

Monitoring Schedule

• Hemoglobin: Check pre-dialysis before the mid-week session at least monthly during ESA therapy to detect rapid rises requiring dose reduction. 1

• Iron parameters: Recheck TSAT and ferritin 4 weeks after starting IV iron, then every 3 months once stable. 1, 3

• Dose reduction trigger: If hemoglobin rises >1 g/dL within 2 weeks or exceeds 12 g/dL, reduce the ESA dose by 25% immediately. 1

---

Additional Considerations in This Complex Patient

Hematochezia and Colon Cancer

The patient reports minimal hematochezia, which contributes to ongoing iron losses beyond dialysis-related losses. 5 With stage IV rectal adenocarcinoma and a history of colostomy, chronic gastrointestinal blood loss is expected. This reinforces the need for:

• Higher maintenance IV iron: Consider the upper end of the maintenance range (100–125 mg weekly) rather than 25 mg weekly to compensate for GI losses. 1

• Serial hemoglobin monitoring: Check hemoglobin weekly until stable, then every 2–4 weeks, to detect acute bleeding episodes. 3

Malignancy-Related Anemia

Cancer-related anemia of chronic disease may blunt ESA response independent of iron status. 3 The patient's stage IV colon cancer, chronic empyema, and elevated inflammatory markers (WBC 15.93, neutrophils 89%) suggest significant chronic inflammation that can:

• Increase hepcidin levels: This blocks iron mobilization from stores, creating functional iron deficiency even when ferritin appears adequate. 6

• Reduce ESA responsiveness: Inflammatory cytokines (IL-6, TNF-α) inhibit erythropoiesis directly. 6

If hemoglobin remains <9 g/dL after 8 weeks of adequate iron supplementation and optimized ESA dosing, consider packed red blood cell transfusion to improve symptoms and quality of life. 3

Chronic Empyema and Infection Risk

The patient's chronic right empyema thoracis increases infection risk with IV iron supplementation. 1 Monitor closely for:

• Signs of active infection: Fever, worsening leukocytosis, chest pain, increased pleural effusion on imaging. 1

• Temporary IV iron hold: If acute infection develops, stop IV iron until resolved, as iron promotes bacterial growth. 1

---

Practical Algorithm Summary

1. Today (Day 0):

   • Confirm chronic empyema is stable (not acutely infected)
   • Start iron sucrose 100 mg IV with each dialysis session (three times weekly)
   • Continue epoetin alfa 4000 U post-dialysis three times weekly
   • Check hemoglobin pre-dialysis weekly

2. Week 4:

   • Recheck TSAT and ferritin
   • If TSAT ≥20% and ferritin ≥100 ng/mL, assess hemoglobin response
   • If hemoglobin increased <1 g/dL, increase epoetin alfa to 5000 U three times weekly
   • Transition to maintenance IV iron 100–125 mg weekly (given GI blood loss)

3. Week 8:

   • Recheck hemoglobin, TSAT, ferritin
   • If hemoglobin still <9 g/dL despite adequate iron (TSAT ≥20%, ferritin ≥100 ng/mL) and optimized ESA dose, consider transfusion
   • If hemoglobin 11–12 g/dL, continue current regimen and monitor monthly

4. Ongoing:

   • Hemoglobin pre-dialysis monthly once stable
   • TSAT and ferritin every 3 months
   • Hold IV iron if ferritin >800 ng/mL or TSAT >50%
   • Reduce ESA dose by 25% if hemoglobin >12 g/dL

---

Common Pitfalls to Avoid

• Do not escalate ESA before correcting iron deficiency: This is the most common error and leads to unnecessary ESA dose escalation, increased cost, and potential harm. 1, 3

• Do not use oral iron in hemodialysis patients: Oral iron cannot overcome dialysis-related losses and hepcidin blockade. 1

• Do not target hemoglobin >12 g/dL: Higher targets increase mortality and cardiovascular events without improving quality of life. 1, 4

• Do not give IV iron during active infection: Defer until infection resolves to avoid promoting bacterial growth. 1

• Do not ignore ongoing blood loss: This patient's hematochezia requires higher maintenance IV iron doses than standard dialysis patients. 5